US Health Agency Bans Funding for Abortion-Fetal Tissue Research
The National Institutes of Health (NIH), the world's largest public funder of biomedical research, has announced it will no longer fund studies that use human fetal tissue obtained from elective abortions. The move marks a significant shift in policy, with the NIH citing a desire to modernize its funding priorities.
According to officials, the decision was made by NIH Director Jay Bhattacharya, who argued that this change would enable the agency to support more advanced research technologies that can better model human health and disease. Under President Trump's leadership, the NIH had already implemented measures in 2019 to review and evaluate research proposals involving fetal tissue.
However, these restrictions were lifted by his successor, Joe Biden in 2021. The decision comes as researchers have faced opposition from anti-abortion groups, who have sought to ban all such studies. The NIH has maintained that the use of human fetal tissue in research is a legitimate area of inquiry, with significant contributions made towards diseases like diabetes, Alzheimer's and infertility.
The agency's move has been met with mixed reactions, with some hailing it as a victory for pro-choice advocates, while others have expressed concern about the potential implications for scientific research. The NIH has acknowledged that funding for studies using fetal tissue from abortions will cease immediately, although researchers will still be able to access tissue from miscarriages.
The decision comes at a time when vaccine development and production are ongoing, with fetal tissue playing a crucial role in the creation of vaccines for polio, hepatitis A, rabies and other diseases. The agency's shift in policy may raise questions about the future of biomedical research and its ability to address pressing health concerns.
The National Institutes of Health (NIH), the world's largest public funder of biomedical research, has announced it will no longer fund studies that use human fetal tissue obtained from elective abortions. The move marks a significant shift in policy, with the NIH citing a desire to modernize its funding priorities.
According to officials, the decision was made by NIH Director Jay Bhattacharya, who argued that this change would enable the agency to support more advanced research technologies that can better model human health and disease. Under President Trump's leadership, the NIH had already implemented measures in 2019 to review and evaluate research proposals involving fetal tissue.
However, these restrictions were lifted by his successor, Joe Biden in 2021. The decision comes as researchers have faced opposition from anti-abortion groups, who have sought to ban all such studies. The NIH has maintained that the use of human fetal tissue in research is a legitimate area of inquiry, with significant contributions made towards diseases like diabetes, Alzheimer's and infertility.
The agency's move has been met with mixed reactions, with some hailing it as a victory for pro-choice advocates, while others have expressed concern about the potential implications for scientific research. The NIH has acknowledged that funding for studies using fetal tissue from abortions will cease immediately, although researchers will still be able to access tissue from miscarriages.
The decision comes at a time when vaccine development and production are ongoing, with fetal tissue playing a crucial role in the creation of vaccines for polio, hepatitis A, rabies and other diseases. The agency's shift in policy may raise questions about the future of biomedical research and its ability to address pressing health concerns.